Description
DROXIDOPA (NORTHERA) 300MG ORAL CAPSULES
First action · last action
2016-09-14 · 2016-09-14
Transactions
1
First transaction's obligation
$6,829
Base + all options value (sum of deltas)
$6,829
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30249
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-09-14+$6,829= $6,829
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-09-14 | +$6,829 | $6,829 | DROXIDOPA (NORTHERA) 300MG ORAL CAPSULES |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI F1M3L99R99B3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79726D0172 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C24920N0537 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $25,476 | FY2020 |
| 36C24920N0520 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $20,381 | FY2020 |
| 36C24920N0515 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $10,191 | FY2020 |
| 36C24920N0502 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $10,191 | FY2020 |
| 36C24920N0482 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $10,191 | FY2020 |
Other recipients under 6810 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26018P3900 | LIFE CHEMICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $80,976 | FY2018 |
| VA26018P2530 | BSE PERFORMANCE, LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $24,960 | FY2018 |
| VA26017F0129 | UNITED THERAPEUTICS CORP | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $91,147 | FY2017 |
| VA26017J3080 | ARIAD PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $79,221 | FY2017 |
| VA26016P1112 | MCKESSON CORPORATION | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $112,285 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26016F1444_3600_V797D30249_3600 · retrieved 2026-09-26.